



Clinical Trials

# Accelerating first-in-human and early phase oncology trials

# Start strong to stay ahead

Early phase oncology clinical trials, encompassing **Phase I and Phase I/II trials**, are the crucial first steps in evaluating new cancer therapies in humans. These trials focus on determining the safety, dose, side effects, and initial efficacy of new drugs.

Our early development oncology services group at the PPD™ clinical research business of Thermo Fisher Scientific is dedicated to transforming innovative research into effective treatments. We specialize in **precision medicine, enrolling biomarker-selected patients** to identify early clinical activity, particularly with targeted or immunotherapy agents.

With a coordinated approach, we anticipate challenges, recruit the right patients, engage top investigators, and design trials that pave the way for later-stage success. Our team combines scientific rigor with operational excellence, offering flexible and personalized solutions for biotech organizations.

Whether advancing your first-in-human trial or managing complex Phase I/II programs, we provide unparalleled support to accelerate your oncology drug development at every step.



# Partner with a CRO that thinks big and works close

We offer personalized and flexible services tailored to the specific needs of each client and trial, delivering the agility and responsiveness that you expect.

Our in-depth knowledge of local regulatory environments and health care systems ensures compliance and smooth trial operations. Furthermore, we are committed to building strong relationships with local investigators and key opinion leaders, fostering trust and collaboration at the local level.

Let us be your early phase partner in oncology – where global strength meets focused dedication.



In the past five years, our experts have supported:



**254+** early phase Hem/Onc studies



**46+** Indications



**10,600+** patients



**3,320** sites around the world



**46+** countries

# Experience with many indications in early phase development



## ONCOLOGY

- Solid tumors
- Non-small-cell lung cancer
- Prostate cancer
- Breast cancer
- Melanoma
- Hepatocellular carcinoma
- Glioblastoma
- Ovarian cancer
- Pancreatic ductal carcinoma
- Colorectal cancer
- Head and neck carcinoma
- Renal cell carcinoma
- Cholangiocarcinoma
- Neuroendocrine carcinoma
- Cachexia



## HEMATOLOGY

- Acute myeloid leukemia
- Multiple myeloma
- Non-Hodgkin lymphoma
- B-cell lymphoma
- Acute lymphoblastic leukemia
- Sickle cell anemia
- Hemophilia B

We have experience in IMPs with various novel modalities such as:

- Checkpoint inhibitors
- Antibody drug conjugate (ADC)
- Bispecific antibodies
- Radiopharmaceuticals
- Therapeutic vaccines
- Cell and gene therapies
- Combination immunotherapies



# Unmatched expertise



## Expert team and innovative solutions

Our early phase oncology services group is structured to provide access to dedicated, hands-on teams embedded within local clinical ecosystems—offering rapid start-up, direct site collaboration and culturally tailored patient engagement strategies. We're present where your trial matters most.

We employ cutting-edge technologies such as AI and machine learning to optimize trial design and execution, enhancing predictive modeling for patient outcomes and trial efficiency. Our Clinical Forecasting Suite, an AI predictive modeling tool to optimize trial design and execution, enhances patient outcomes and trial efficiency.

We utilize decentralized clinical trial (DCT) models and virtual trial designs to increase patient accessibility and convenience, particularly in diverse and remote populations.



## Trusted site network

With nearly 100 sites across North America, Asia-Pacific, Europe and the Middle East, Latin America, and Africa, our global network of early phase units and oncology-focused sites ensures access to high-performing investigators and ready-to-enroll patient populations, reducing trial timelines and improving data quality.

From specialized cancer centers to academic institutions and private networks, we bring together precision and reach.



## We think like a startup and deliver like a global leader

We offer the scalability and technology of global leaders, while delivering the cost-effectiveness and flexibility associated with trusted mid-size partners. Our clients don't have to choose between world-class capabilities and high-touch service — with us, they get both.




# Proven experience with a personal touch

With decades of oncology experience and more than 250 early phase oncology studies conducted in the past five years, we combine therapeutic depth with agile processes, along with a team specifically aligned with a biotech's expectations.

Our experts in regulatory science, clinical operations, biostatistics and data management don't just consult — they embed into your team, offering adaptive strategies tailored to your molecule, goals and timelines.

You can rely on us as an experienced early phase oncology partner for your study, with 2024 performance metrics that demonstrate our ability to accelerate startup in a crowded study landscape:

## PPD vs Industry\* In 2024 in Phase I oncology



\*Source: CADM snowflake for CRG studies (2020-2025)/ KMR portal for Industries studies (2020-2024)

# Capabilities designed to address key challenges in early phase development




# Transforming biotech innovations into market success

The path to success in biotech is personal and challenging, which is why we're here to walk it with you. From proving product viability to navigating a complex regulatory landscape, our mission is to simplify your drug development journey while driving results.

Your focus is on innovation. Ours is on accelerating it. With a comprehensive suite of services tailored for small to mid-sized biotech companies, we bring expertise and efficiency to every phase of development — from pre-clinical research to global commercialization.

We're more than a service provider — we're your partner in innovation. Our specialized teams bring deep industry knowledge and a commitment to your goals.



## Why biotech startups choose us for early phase oncology

- **We work the way you work—agile, focused, and fast.**
- **Flexible pricing** designed for emerging companies with **adaptive planning** to align with funding cycles and milestones
- **Hands-on support** from senior-level oncology experts
- **Efficient site activation** via our embedded proximity teams and early phase site network
- **Integrated data, biomarker, and regulatory strategy** from day one with a patient-centric approach
- **High-quality and reliable data**, thanks to our rigorous quality management systems and adherence to global standards.
- **End-to-end solutions** that comprise **comprehensive capabilities** to accelerate and streamline the clinical trial process.



**Your Vision. Our Science. One Path Forward.**

Talk to us about how we can accelerate your clinical trial with our expertise in early phase oncology.

 Learn more at [ppd.com](https://www.ppd.com)

**ppd**